References
- Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994; 19–20: 219–40
- Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14: 280–90
- Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905–10
- Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425–9
- Cameron DA, Cornbleet MC, MacKie RM, Hunter JA, Gore M, Hancock B, et al. Adjuvant interferon alpha 2b in high risk melanoma-the Scottish study. Br J Cancer 2001; 84: 1146–9
- Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH, et al. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17
- World Health Organization. Hepatitis C: Prevention and treatment: Contraindications to interferon therapy for chronic hepatitis C. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index5.html#contraint.
- Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006; 54: 2335–7
- Kötter I, Müller CA, Einsele H, Mohren M, Kanz L. Interferon-alpha-associated polyarthritis. Possible induction of seropositive rheumatoid arthritis by interferon-alpha: Two case reports and review of the literature. Z Rheumatol 1999; 58: 185–95
- Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283–91
- Johnson DM, Hayat SQ, Burton GV. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma. J Rheumatol 1999; 26: 1009–10
- Passos de Souza E, Evangelista Segundo PT, José FF, Lemaire D, Santiago M. Rheumatoid arthritis induced by alpha-interferon therapy. Clin Rheumatol 2001; 20: 297–9
- Silman AJ. Epidemiology and rheumatic diseases. Oxford textbook of rheumatology2nd ed, PJ Maddison. Oxford University Press, Oxford 1998; 811–28
- Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709–18
- Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007; 121: 2562–6